How Dangerous Is Qualigen Therapeutics’ Cash Burn?

Qualigen Therapeutics has a market capitalization of US$76 million and spent US$14 million last year, or 18 percent of its market value. As a result, we believe the company could easily raise additional capital for expansion, albeit at the cost of some dilution.

History Tells Us the Stock Market Rally Will Continue Through Christmas |  Fortune

Even though Qualigen Therapeutics ‘NASDAQ QLGN at growing currency burn makes us nervous, we feel compelled to mention that we thought its cash runway was relatively promising. To summarize, based on the factors discussed in this article, we believe Qualigen Therapeutics’ cash burn is a risk. On the other hand, Qualigen Therapeutics has five warning signs (one of which is particularly unpleasant) that we believe you should be aware of.

If you’d rather look at a company with stronger fundamentals, check out this free list of interesting companies with a high return on equity and low debt or this list of stocks that are all expected to grow.

Fulgent Genetics, Inc. (NASDAQ: FLGT) reported fourth-quarter revenue of $295 million, an increase of over 3,400% year over year. The non-GAAP net income came in at $6.20 per share, beating analysts’ expectations of $4.02 per share.

In after-hours trading, the stock jumped 34.46 percent to $115.

Acorda Therapeutics Inc (NASDAQ: ACOR) reported $38.16 million in fourth-quarter revenues for the fiscal year 2020, down from $50.50 million the previous year. The company went from a profit of $8.26 per share to a loss of $9.82 per share.

In after-hours trading, the stock fell 11.5 percent to $6.

The fourth-quarter revenues of Opiant Pharmaceuticals Inc (NASDAQ: OPNT) increased from $7.67 million in 2019 to $9.924 million in 2020. The company went from a profit of 20 cents per share to a loss of 16 cents per share. On $9.92 million in revenue, consensus estimates predicted a profit of 7 cents per share.The stock rose 5.34 percent to $14 in after-hours trading.

DermTechInc (NASDAQ: DMTK) reported $2.1 million in fourth-quarter revenue, up 33% year over year. The net loss per share increased to 43 cents from 48 cents previously. According to the company, the company expects first-quarter assay revenue to be between $1.6 and $1.9 million. In after-hours trading, the stock fell 7.95 percent to $48.77.

PDUFA Dates That Shouldn’t Be Missed

Yescarta, or axicabtageneciloleucel, is being evaluated to treat relapsed or refractory follicular lymphoma and marginal zone lymphoma after two or more prior lines of systemic therapy Gilead Sciences, Inc. (NASDAQ: GILD). Yescarta is a CAR T-cell therapy that Gilead acquired through the Kite acquisition. For more stocks such as nasdaq fb, you can check at